

Platelet-Neutrophil Aggregate formation induces NLRP3 inflammasome activation in vaccine induced thrombotic thrombocytopenia (VITT)

STEPHANE VICENTE ROZINI^{1,2} REMY MARTINS-GONÇALVES^{1,2}; DANIELA P. MENDES-DE-ALMEIDA^{3,4,5}; CAROLINA Q. SACRAMENTO¹; GEAN CARLO PEREIRA-SILVA¹¹; JOANNA BOKEL^{4,7}; GABRIELLEN VITIELLO TEIXEIRA⁸; VICTOR BERTOLLO GOMES PORTO⁹; SANDRA WAGNER CARDOSO⁴; BRENDA HOAGLAND⁴; PATRICIA MOUTA NUNES DE OLIVEIRA¹⁰; LUIZ AMORIM FILHO¹¹; BEATRIZ GRINSZTEJN⁴; MARIA DE LOURDES DE SOUSA MAIA¹⁰; EUGÊNIO D. HOTTZ⁹; PATRICIA T. BOZZA¹.

¹Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; ²Postgraduate program in Immunology and Inflammation – Federal University of Rio de Janeiro, Brazil (UFRJ); ³Department of Medical Affairs, Clinical Studies, and Post-Registration Surveillance (DEAME), Institute of Technology in Immunobiologicals/Bio-Manguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil; ⁴Instituto Nacional de Infectologia Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; ⁵Research Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil; ⁶Laboratory of Immunothrombosis, Department of Biochemistry, Federal University of Juiz de Fora, Juiz de Fora, Brazil; ⁷Onc-Hematology Unit, Clínica São Vicente, Rio de Janeiro, Brazil; ⁸Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil; ⁹General Coordination of the National Immunization Program/National Immunization Program/ Brazilian Ministry of Health, Brazil; ¹⁰Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil; ¹¹Hemorio, Rio de Janeiro, Brazil. ¹¹Laboratory Innate Immunity, Paulo Góes Institute of Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil;

HYPOTHESIS

Formation of platelet-leukocyte aggregates (PLAs) and inflammasome activation are common features of thromboinflammatory diseases. Here we hypothesized that PLA formation and inflammasome activation might be involved in the development of VITT.




Figure 1 – Hypothesis.

STUDY DESIGN

Samples of Individuals (n=57) with post-vaccine thrombosis (PVT) were collected in the entire Brazilian territory as part of pharmacovigilance. Samples from individuals vaccinated with adenovirus vector vaccines (AVV) were sorted according guidelines by the likelihood that these events are VITT related (NEJM. 385:1680-1689, 2021). Age/sex matched unvaccinated (UV) individuals were also included (CAAE-48532621.8.0000.5262/52396621.0.0000.5262).

Criteria:	Definite VITT:
<ul style="list-style-type: none"> Presence of thrombosis Onset of symptoms 5-30 days after vaccination Thrombocytopenia (<150.000 platelets/μL) Positive Anti-PF4 antibodies (ELISA) D-dimer >4000μg/mL (>2000μg/mL) D-dimer <2000μg/mL = exclusion criteria Unknown D-dimer = possible 	<ul style="list-style-type: none"> All criteria met
	Probable VITT:
	<ul style="list-style-type: none"> 4 criteria 3 criteria with D-dimer 2000 - 4000μg/mL
	Possible VITT:
	<ul style="list-style-type: none"> 3 criteria 2 criteria with D-dimer 2000 - 4000μg/mL
	Unlikely VITT:
	<ul style="list-style-type: none"> 2 criteria

Figure 2 – VITT classification. Defined by the occurrence of thrombosis between 5-30 days post vaccination associated with thrombocytopenia, high D-dimer and presence of anti-PF4 Ab.

METHODOLOGY

COHORT

57 individuals that presented with thrombosis following AVV (PVT) were sorted according to the number of VITT criteria met. 20 were classified as unlikely VITT, 7 as possible VITT, 18 as probable VITT and 12 as definite VITT. The samples were compared with samples from 28 age and sex matching unvaccinated individuals (Figure 3).





Figure 3 – Cohort. 57 PVTs were compared with age and sex matched Unvaccinated Volunteers. Median, 25th and 75th quartiles and range are shown.

Ex-vivo experiment



To investigate PLA assays, we performed ex-vivo plasma exchange substituting the platelet-poor plasma (PPP) from healthy volunteers' (HV) whole blood with PPP from DV or Unvaccinated individuals for 1, 3 and 6 hours, and evaluating through flow cytometry the PLA formation and inflammasome activation.

RESULTS

Thromboinflammation in PVTs

PVT patients as a whole had lower platelet counts, elevated D-dimer levels and lower fibrinogen levels (Figure 4D-F).




Figure 4 – Hypercoagulability of patients with postvaccination thrombosis (PVT). Platelet count (D) and plasma concentrations of (E) D-dimer, (F) fibrinogen.

As expected, PVTs also displayed higher plasmatic levels of the thromboinflammatory molecules p-selectin (CD62p) and Tissue Factor (Figure 4G and H).




Figure 4 (continued) – Hypercoagulability of patients with postvaccination thrombosis (PVT). (G) tissue factor and (H) CD62p of Unvaccinated (n=28) and PVTs (n=57) according to their VITT classification. The normal clinical range is displayed in the orange area, boxes represent the median and 25th and 75th quartiles, and whiskers display the range. Asterisks indicate significant differences in patients with different VITT classifications compared to the unvaccinated group. *p<0.05, **p<0.01 and ***p<0.001. The black solid and ticked lines represent the median and 25th and 75th quartiles, respectively, of the unvaccinated group.

Inflammasome activation in PVTs

Inflammasome assembly, followed by Caspase-1 activation and secretion of IL-1 β and L-18 are characteristics of VITT.




Figure 5 – Inflammasome Activation in Definite VITT. Definite VITT cases presented higher IL-18 (A) and IL-1 β (B) then Unlikely and Caspase-1 (C) in the plasma of PVTs stratified according to VITT likelihood classification. Median, 25th and 75th quartiles and range are shown. Grey areas and lines represent de interquartile range and median of the unvaccinated controls.

The VITT milieu induces platelet-granulocyte aggregate formation and caspase-1 activation

At all-time points, Definite VITT plasma induced increased activation of caspase-1 in granulocytes (CD15+) and platelet-granulocyte aggregate (PGA) formation was increased at 3 and 6 hours after incubation with VITT plasma.




Figure 6 – Definite VITT plasma leads to Caspase-1 activation in HV Granulocytes. Granulocytes isolated from healthy donors and incubated with VITT plasma were analysed by flow cytometry. Percentage of HV CD15⁺ cells expressing the active form of Caspase-1 after incubation with Definite VITT plasma for 1, 3 or 6 hours. Median, 25th and 75th quartiles and range are shown.




Figure 6 (continued) - (C) The gating strategy was used to determine the expression of caspase-1 in platelet-free granulocytes (CD15⁺/CD41⁻) or PNAs (CD15⁺/CD41⁺). In platelet-free granulocytes, caspase-1 activation was not increased in the blood reconstituted with Definite VITT plasma compared to the plasma from Unvaccinated individuals (D), but platelet-granulocyte aggregates had increased activation of caspase-1 (E) after incubation with 50% of Definite VITT plasma.

PNA formation triggers caspase-1 activation in cells exposed to VITT plasma. PNA formation occurs through Fc γ RIIa and caspase-1 activation through the NLRP3 inflammasome




Figure 7 – Definite VITT plasma induces aggregation through Fc γ RIIa- and NLRP3 inflammasome-dependent caspase-1 activation. Isolated platelet-neutrophils were stimulated with 50% of Definite VITT or unvaccinated individuals plasma. (B) Percentage of total neutrophils aggregated with platelets. (C) Percentage of platelet-free neutrophils and (D) PNAs expressing the active form of caspase-1 after incubation with 50% plasma from unvaccinated or definite VITT patients for 3 hours. We used an Fc γ RII neutralizing antibody (IV.3) or an NLRP3 inhibitor (MCC950) prior to incubation with VITT or unvaccinated plasma. (F) Percentage of total neutrophils expressing active caspase-1, (G) percentage of neutrophils aggregated with platelets, (H) percentage of platelet-free neutrophils and (I) percentage of PNAs expressing caspase-1 after 30 minutes of pretreatment with IV.3 or MCC950 (platelets and neutrophils) followed by incubation with 50% plasma from Definite VITT (n=10) or unvaccinated (n=10) individuals.

CONCLUSION

Individuals that developed VITT after immunization with adenovirus vector based SARS-CoV-2 vaccines displayed elevated IL-1 β , IL-18 and activated Caspase-1 in the plasma, indicating that inflammasome assembly is a characteristic of VITT. Our data also suggest that factors present in the plasma of VITT patients are capable of promoting the formation of platelet-neutrophil aggregates in a Fc γ RIIa-dependent manner, which in turn leads to the activation of pro-caspase-1 via the NLRP3 inflammasome.